Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Artrya Limited ( (AU:AYA) ) has issued an update.
Artrya Limited has completed Tranche 2 of its share placement, issuing 7,175,588 fully paid ordinary shares at $2.05 each, raising approximately $14.7 million. This capital injection is expected to bolster Artrya’s operations and enhance its market positioning as it continues to commercialize its AI-powered Salix platform for coronary artery disease management, potentially impacting stakeholders positively by advancing its technological and market goals.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company specializing in AI-powered solutions for the detection and management of coronary artery disease. Their proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient diagnoses. The company is focused on advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 872,395
Technical Sentiment Signal: Buy
Current Market Cap: A$496.2M
Learn more about AYA stock on TipRanks’ Stock Analysis page.